Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE

被引:14
作者
Hasdemir, Davut B. [1 ]
Davila, Lukas Aguirre [2 ]
Schweitzer, Nora [3 ]
Meyer, Bernhard C. [1 ]
Koch, Armin [2 ]
Vogel, Arndt [3 ]
Wacker, Frank [1 ]
Rodt, Thomas [1 ]
机构
[1] Hannover Med Sch, Inst Diagnost & Intervent Radiol, Hannover, Germany
[2] Hannover Med Sch, Inst Biometry, Hannover, Germany
[3] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
关键词
TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; INTERNATIONAL EXPERT PANEL; TRANSARTERIAL CHEMOEMBOLIZATION; CONSENSUS RECOMMENDATIONS; TUMOR RESPONSE; EMBOLIZATION; MODALITIES; CRITERIA; TRIAL;
D O I
10.5152/dir.2016.16006
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE Transarterial chemoembolization (TACE) is an established treatment for intermediate stage hepatocellular carcinoma (HCC). The aim of this retrospective study was to evaluate the power of lesion vascularization criteria based on computed tomography for prognosis of overall survival before initiation of treatment. METHODS A total of 59 patients with intermediate stage HCC treated with TACE as first-line treatment were retrospectively evaluated. TACE procedures were performed using doxorubicin, cisplatin, and lipiodol. Response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) were used to determine the initial tumor response. Four vascularization patterns (VP) of the largest target lesion (homogeneous vascularization [VP1], homogeneous vascularization with additional arterial hypervascularization [VP2], heterogeneous vascularization with [VP3] and without zones of hypervascularization [VP4]) were assessed prior to the first TACE and correlated to survival. RESULTS Kaplan-Meier analysis yielded a median overall survival of 608 days (standard error [SE], 120.5 days). Survival analysis showed significant differences depending on the vascularization patterns (P = 0.012; hazard ratio, 0.327): patients with homogeneously vascularized lesions (VP1, VP2) had a median overall survival of 1091 days (SE, 235.5 days). Patients with heterogeneous vascularization of the lesion (VP3 and VP4) showed a median overall survival of 508 days (SE, 113.9 days). CONCLUSION The vascularization pattern of the largest HCC lesion is helpful for survival prognosis under TACE treatment and therefore has the potential to be used as an additional parameter for treatment stratification.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 29 条
[1]   Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature [J].
Abdel-Rahman, O. ;
Elsayed, Z. A. .
DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (12) :3389-3396
[2]   Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone [J].
Brown, Karen T. ;
Do, Richard K. ;
Gonen, Mithat ;
Covey, Anne M. ;
Getrajdman, George I. ;
Sofocleous, Constantinos T. ;
Jarnagin, William R. ;
D'Angelica, Michael I. ;
Allen, Peter J. ;
Erinjeri, Joseph P. ;
Brody, Lynn A. ;
O'Neill, Gerald P. ;
Johnson, Kristian N. ;
Garcia, Alessandra R. ;
Beattie, Christopher ;
Zhao, Binsheng ;
Solomon, Stephen B. ;
Schwartz, Lawrence H. ;
DeMatteo, Ronald ;
Abou-Alfa, Ghassan K. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (17) :2046-+
[3]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[4]   Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design [J].
Burrel, Marta ;
Reig, Maria ;
Forner, Alejandro ;
Barrufet, Marta ;
Rodriguez de Lope, Carlos ;
Tremosini, Silvia ;
Ayuso, Carmen ;
Llovet, Josep M. ;
Isabel Real, Maria ;
Bruix, Jordi .
JOURNAL OF HEPATOLOGY, 2012, 56 (06) :1330-1335
[5]   Transarterial chemoembolization for unresectable hepatocellular carcinoma:: Meta-analysis of randomized controlled trials [J].
Cammà, C ;
Schepis, F ;
Orlando, A ;
Albanese, M ;
Shahied, L ;
Trevisani, F ;
Andreone, P ;
Craxì, A ;
Cottone, M .
RADIOLOGY, 2002, 224 (01) :47-54
[6]   Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate [J].
Cescon, Matteo ;
Cucchetti, Alessandro ;
Ravaioli, Matteo ;
Pinna, Antonio Daniele .
JOURNAL OF HEPATOLOGY, 2013, 58 (03) :609-618
[7]   Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel [J].
Cheng, Ann Lii ;
Amarapurkar, Deepak ;
Chao, Yee ;
Chen, Pei-Jer ;
Geschwind, Jean-Francois ;
Goh, Khean L. ;
Han, Kwang-Hyub ;
Kudo, Masatoshi ;
Lee, Han Chu ;
Lee, Rheun-Chuan ;
Lesmana, Laurentius A. ;
Lim, Ho Yeong ;
Paik, Seung Woon ;
Poon, Ronnie T. ;
Tan, Chee-Kiat ;
Tanwandee, Tawesak ;
Teng, Gaojun ;
Park, Joong-Won .
LIVER INTERNATIONAL, 2014, 34 (02) :174-183
[8]   Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma [J].
Donati, Olivio F. ;
Do, Richard Kinh Gian ;
Hoetker, Andreas M. ;
Katz, Seth S. ;
Zheng, Junting ;
Moskowitz, Chaya S. ;
Beattie, Christopher ;
Brown, Karen T. .
EUROPEAN RADIOLOGY, 2015, 25 (09) :2779-2788
[9]   Chemoembolization for intermediate HCC: Is there proof of survival benefit? [J].
Forner, Alejandro ;
Llovet, Josep M. ;
Bruix, Jordi .
JOURNAL OF HEPATOLOGY, 2012, 56 (04) :984-986
[10]   EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation [J].
Gillmore, Roopinder ;
Stuart, Sam ;
Kirkwood, Amy ;
Hameeduddin, Ayshea ;
Woodward, Nick ;
Burroughs, Andrew K. ;
Meyer, Tim .
JOURNAL OF HEPATOLOGY, 2011, 55 (06) :1309-1316